MDCX News & Events

Medicus Pharma announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and Drug Administration for SkinJect, D-MNA, for the treatment of basal cell carcinoma, BCC, in patients with Gorlin Syndrome, a rare genetic disorder characterized by the development of multiple, recurrent skin cancers. The submission represents a strategic expansion of the SkinJect program into a high unmet need orphan indication, where current treatment options are limited and often involve repeated surgical procedures associated with cumulative morbidity and disfigurement.

Medicus Pharma entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor platforms. The campaign will highlight Medicus Pharma's differentiated pipeline, including SkinJect, a localized immuno-oncology platform targeting non-melanoma skin cancers such as basal cell carcinoma and rare conditions like Gorlin Syndrome, representing a multi-billion-dollar market opportunity. The series will also feature Teverelix, a next-generation GnRH antagonist designed for patients with advanced prostate cancer and acute urinary retention associated with enlarged prostate conditions-addressing a significant and growing global market. Under the agreement, New to The Street will produce and distribute a comprehensive media campaign designed to elevate Medicus Pharma's corporate narrative, clinical progress, and long-term growth strategy to a broad investor audience. he series will include 12 in-depth executive interviews released monthly, with each segment broadcast across Bloomberg Television in the United States.

Medicus Pharma announced the company has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention in men with benign prostatic hyperplasia as part of its existing open investigational new drug for Teverelix.